跳转至内容
Merck
CN

A1010

氧化砷(III)

ReagentPlus®, ≥99.0%

别名:

三氧化二砷, 亚砷酸

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
As2O3
化学文摘社编号:
1327-53-3
分子量:
197.84
NACRES:
NA.55
PubChem Substance ID:
329770647
UNSPSC Code:
12171602
EC Number:
215-481-4
MDL number:
MFCD00003433
Assay:
≥99.0%
Form:
powder

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氧化砷(III), ReagentPlus®, ≥99.0%

InChI key

IKWTVSLWAPBBKU-UHFFFAOYSA-N

InChI

1S/As2O3/c3-1-5-2-4

SMILES string

O=[As]O[As]=O

vapor pressure

0 hPa ( 66 °C)

product line

ReagentPlus®

assay

≥99.0%

form

powder

storage temp.

room temp

Quality Level

200

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

氧化砷（III）已被用于一项详细研究三氧化二砷与γ辐射结合以阐明血红蛋白（Hb）效果的研究中。

Biochem/physiol Actions

针对急性早幼粒细胞白血病（APL）的强效剂。引起皮肤癌、肺癌和膀胱癌。

General description

氧化砷（III），也称为三氧化二砷，是一种可用作合成多种砷基化合物原料的两性氧化物。它可用于使玻璃和搪瓷脱色。它在治疗急性早幼粒细胞白血病（APL）中的功效已被研究。

Legal Information

ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1

target_organs

Respiratory system,Cardio-vascular system,Gastrointestinal tract

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCP2567
BCCL3474
BCCM5851
BCCJ8941
BCCG8449

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  4. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  5. How should product A1010, Arsenic(III) oxide be dissolved?

    This product is soluble in 1 M NaOH  at 66 mg/ml, with heat as needed, yielding a clear, colorless solution.  This information can be found on the Product Information Sheet.

  6. What is the solution stablity of A1010, Arsenic(III) oxide?

    We do not have any solution stability data for product A1010. Thus it is best to make up fresh solutions of A1010.

  7. What is the difference between Product Nos. A1010 and 202673, Arsenic(III) oxide?

    Both products are Arsenic(III) oxide.  The specifications for the products differ. Please see the Specification Sheets for details.

  8. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Combined effect of arsenic trioxide and radiation on physical properties of hemoglobin biopolymer.
Saad-El-Din AA, et al.
Journal of Radiation Research and Applied Sciences, 7(2), 411-416 (2014)
Wilson H Miller et al.
Cancer research, 62(14), 3893-3903 (2002-07-19)
Arsenic trioxide has shown substantial efficacy in treating both newly diagnosed and relapsed patients with acute promyelocytic leukemia (APL). As a single agent, it induces complete remissions, causing few adverse effects and only minimal myelosuppression. These successes have prompted investigations
E Lengfelder et al.
Leukemia, 26(3), 433-442 (2011-09-10)
Arsenic trioxide (ATO) is presently the most active single agent in the treatment of acute promyelocytic leukemia (APL). This review provides insights into the mode of action and the pharmacological properties of ATO, and summarizes the most relevant results of
Dikshith TSS
Handbook of Chemicals and Safety, 92-92 (1992)
Z X Shen et al.
Blood, 89(9), 3354-3360 (1997-05-01)
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATRA) induced and chemotherapy maintained complete remission (CR). As2O3 was administered intravenously at
查看所有相关文献

相关内容

Product Information Sheet - A1010

Product Information Sheet

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持